Leap Therapeutics Inc (LPTX): Debt to Equity
Leap Therapeutics, Inc. (LPTX) develops therapies to combat gastrointestinal tumors, leveraging AI and robotics to accelerate antibody synthesis. This price chart illustrating trading dynamics shows a debt-to-equity ratio of 0.05. The business relies on a network of US oncology centers for patient recruitment, aiming for market dominance following drug approval by the stringent FDA regulator.
%20Debt%20to%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_LPTX_-_Leap-Therapeutics-Inc._-_Debt-to-Equity-Ratio "LPTX - Leap Tx Total Debt to Capital over the range 07/04/2022 - 11/13/2025 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Leap Therapeutics (LPTX)
The operational model efficiency of Leap Therapeutics, Inc. (LPTX) directly impacts the calculated 0.05 ratio, which measures the proportion of debt within the liability structure relative to equity to assess credit vulnerability. The stability of antibody cold chain logistics minimizes resource shortage risks, which is reflected in the debt-to-equity ratio dynamics, allowing investors to judge the degree of the business's financial autonomy.